PriceTargets.com logo

NASDAQ:GDRX - GoodRx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.93
  • Forecasted Upside: 3.46 %
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$46.33 As of 09/23/2021 01:00 AM ET
▲ +0.8 (1.76%)

This chart shows the closing price for GDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GoodRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDRX

Analyst Price Target is $47.93
▲ +3.46% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for GoodRx in the last 3 months. The average price target is $47.93, with a high forecast of $70.00 and a low forecast of $29.00. The average price target represents a 3.46% upside from the last price of $46.33.

This chart shows the closing price for GDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 polled investment analysts is to buy stock in GoodRx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/27/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/25/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021Credit Suisse GroupBoost Price TargetOutperform$45.00 ➝ $52.00Low
8/31/2021BarclaysUpgradeEqual Weight ➝ Overweight$45.00Medium
8/24/2021CowenLower Price TargetOutperform$44.00 ➝ $42.00High
8/15/2021SVB LeerinkInitiated CoverageBuy$56.00High
8/13/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$45.00Medium
7/2/2021Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $38.00Low
5/27/2021Robert W. BairdInitiated CoverageNeutral$37.00Low
5/18/2021Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$50.00 ➝ $45.00Low
5/14/2021SVB LeerinkLower Price TargetOutperform$61.00 ➝ $56.00High
5/14/2021Royal Bank of CanadaLower Price TargetOutperform$56.00 ➝ $50.00High
5/14/2021BarclaysLower Price TargetEqual Weight$43.00 ➝ $33.00High
5/14/2021CitigroupBoost Price TargetBuy$53.00 ➝ $70.00High
5/10/2021CowenLower Price TargetOutperform$70.00 ➝ $58.00High
3/15/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $50.00Low
3/12/2021BarclaysBoost Price Target$35.00 ➝ $45.00Low
3/12/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$31.00 ➝ $37.00High
3/4/2021SVB LeerinkReiterated RatingBuy$61.00Medium
2/12/2021CowenBoost Price TargetOutperform$50.00 ➝ $70.00Low
1/25/2021GuggenheimInitiated CoverageBuy$52.00High
11/23/2020The Goldman Sachs GroupLower Price TargetNeutral$49.00 ➝ $44.00Low
11/20/2020Credit Suisse GroupLower Price TargetOutperform$60.00 ➝ $49.00Low
11/19/2020BarclaysLower Price TargetEqual Weight$55.00 ➝ $35.00High
11/19/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$56.00High
11/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$36.00Low
11/18/2020JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$29.00Low
11/18/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$50.00 ➝ $31.00High
11/17/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$29.00High
10/19/2020The Goldman Sachs GroupInitiated CoverageNeutral$48.00High
10/19/2020CowenInitiated CoverageOutperform$63.00High
10/19/2020Morgan StanleyInitiated CoverageOverweight$57.00High
10/19/2020JPMorgan Chase & Co.Initiated CoverageNeutral$59.00High
10/19/2020Raymond JamesInitiated CoverageEqual Weight ➝ Market Perform$57.00 ➝ $61.00High
10/19/2020Credit Suisse GroupInitiated CoverageOutperform$60.00High
10/19/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$50.00High
10/19/2020Royal Bank of CanadaInitiated CoverageSector Perform$55.00High
10/19/2020Bank of AmericaInitiated CoverageNeutral$58.00High
10/19/2020UBS GroupInitiated CoverageBuy$64.00High
10/19/2020BarclaysInitiated CoverageEqual Weight$53.00High
10/19/2020SVB LeerinkInitiated CoverageOutperform$61.00High
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 23 positive mentions
  • 10 negative mentions
  • 6 very negative mentions
Mentions as of
2/26/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2021
  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2021
  • 9 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2021
  • 9 very positive mentions
  • 32 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2021

Current Sentiment

  • 9 very positive mentions
  • 32 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

GoodRx logo
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
Read More

Today's Range

Now: $46.33
Low: $45.86
High: $47.38

50 Day Range

MA: $36.63
Low: $29.63
High: $46.98

52 Week Range

Now: $46.33
Low: $26.66
High: $64.22

Volume

1,190,953 shs

Average Volume

1,981,469 shs

Market Capitalization

$18.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?

The following Wall Street research analysts have issued reports on GoodRx in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GDRX.

What is the current price target for GoodRx?

15 Wall Street analysts have set twelve-month price targets for GoodRx in the last year. Their average twelve-month price target is $47.93, suggesting a possible upside of 3.5%. Citigroup Inc. has the highest price target set, predicting GDRX will reach $70.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $29.00 for GoodRx in the next year.
View the latest price targets for GDRX.

What is the current consensus analyst rating for GoodRx?

GoodRx currently has 1 sell rating, 5 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GDRX will outperform the market and that investors should add to their positions of GoodRx.
View the latest ratings for GDRX.

What other companies compete with GoodRx?

Other companies that are similar to GoodRx include Fiserv, Workday, Verisk Analytics, Bilibili, RingCentral, PagSeguro Digital, Clarivate, Zendesk, Globant, StoneCo, ironSource, Five9, Pegasystems, Playtika and Proofpoint.

How do I contact GoodRx's investor relations team?

GoodRx's physical mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company's listed phone number is 855-268-2822 and its investor relations email address is [email protected] The official website for GoodRx is www.goodrx.com.